Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 7INDUSTRY 4OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 4Cisplatin 3pembrolizumab 2fludarabine 2apatinib 2XELOX 2S 1 (combination) 2Paclitaxel 2Oxaliplatin 2Nivolumab 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Irinotecan 2Injections 2Gemcitabine 2Fulvestrant 2Epirubicin 2Drug Therapy 2Boron Neutron Capture Therapy 2titanium silicide 1tislelizumab 1surufatinib 1sintilimab 1pegfilgrastim 1nimotuzumab 1ipatasertib 1ferumoxides 1famitinib 1eribulin 1dalpiciclib 1dactolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER_GOV × Pharmaceutical Preparations × Clear all
NCT01027676 2013-11-14

Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)

National Cancer Center, Korea

Phase 1/2 Unknown
50 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡